Pharmaceuticals - Indian - Bulk Drugs
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 724.97 | 621.05 | 522.90 | 341.99 | 242.49 |
Total Expenses | 610.98 | 508.88 | 431.45 | 270.26 | 207.73 |
Profit Before Tax | 81.90 | 112.17 | 91.45 | 71.73 | 34.75 |
Profit After Tax | 48.71 | 83.29 | 71.95 | 54 | 27.47 |
Operating Profit after Depreciation | 119.93 | 114.58 | 97.86 | 77.34 | 40.34 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 427.16 | 263.23 | 205.60 | 186.31 | 85.19 |
Total Non Current Assets | 600.09 | 309.81 | 229.31 | 197.04 | 110.86 |
Total Current Assets | 495.81 | 457.13 | 429.57 | 216.23 | 121.04 |
TOTAL ASSETS | 1,095.90 | 766.94 | 658.88 | 413.27 | 231.89 |
Total Shareholder's Fund | 674 | 593.96 | 522.27 | 166.93 | 111.81 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 125.17 | 65.53 | -11.93 | 27.96 | 27.08 |
Net Cash used in Investing Activities | -365.36 | -33.04 | -120.72 | -101.21 | -23.94 |
Net Cash used in Financing Activities | 239.36 | -12.25 | 140.26 | 72.11 | 0.19 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 701.37 | 621.05 | 522.90 | 341.94 | 242.42 |
Total Expenses | 600.51 | 508.83 | 431.45 | 270.21 | 207.66 |
Profit Before Tax | 69.11 | 112.22 | 91.45 | 71.73 | 34.75 |
Profit After Tax | 43.68 | 83.34 | 71.95 | 54 | 27.47 |
Operating Profit after Depreciation | 106.76 | 114.64 | 97.86 | 77.34 | 40.34 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 357.06 | 226.37 | 178.95 | 160.61 | 62.18 |
Total Non Current Assets | 600.20 | 304.75 | 227.90 | 197.15 | 111.43 |
Total Current Assets | 471.05 | 454.71 | 426.71 | 213.14 | 116.60 |
TOTAL ASSETS | 1,071.25 | 759.46 | 654.61 | 410.29 | 228.03 |
Total Shareholder's Fund | 675.12 | 586.79 | 518 | 163.95 | 107.98 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 100.85 | 55.73 | -9.69 | 26.92 | 27.25 |
Net Cash used in Investing Activities | -337.32 | -20.47 | -122.47 | -100.74 | -24.48 |
Net Cash used in Financing Activities | 235.48 | -14.44 | 140.26 | 72.11 | 0.19 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 246.73 | 176.67 | 224.96 | 166.44 | 172.36 |
Total Expenses | 197.80 | 147.15 | 181.80 | 139.93 | 147.54 |
Profit Before Tax | 50.04 | 19.95 | 37.20 | 23.70 | -9.94 |
Profit After Tax | 37.57 | 14.69 | 25.68 | 17.81 | -17.02 |
Operating Profit after Depreciation | 57.37 | 30.56 | 44.50 | 30 | 26.32 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 243.59 | 171.14 | 219.94 | 161.70 | 163.60 |
Total Expenses | 195.46 | 144.84 | 179.79 | 138.17 | 144.98 |
Profit Before Tax | 50.02 | 18.21 | 42.28 | 20.34 | -16.04 |
Profit After Tax | 37.68 | 13.72 | 32.08 | 15.70 | -20.96 |
Operating Profit after Depreciation | 56.71 | 28.20 | 48.70 | 26.40 | 19.88 |
₹3/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Ami Organics Ltd | ₹1,981.25 | ₹8,110.14 |
Sun Pharmaceuticals Industries Ltd | ₹1,761.80 | ₹4,22,714.84 |
Divis Laboratories Ltd | ₹5,818.40 | ₹1,54,460.24 |
Cipla Ltd | ₹1,427.30 | ₹1,15,270.75 |
Dr Reddys Laboratories Ltd | ₹1,288.45 | ₹1,07,511.36 |
Torrent Pharmaceuticals Ltd | ₹3,157.60 | ₹1,06,862.73 |
29 Oct 2024, 01:03 pm
23 Oct 2024, 04:17 pm
14 Oct 2024, 06:49 pm
03 Sep 2024, 05:11 pm
03 Sep 2024, 11:39 am